Biotech 365

Main menu

Skip to primary content
Skip to secondary content
  • Biotech 365
    • Contact
    • Offers
  • Biotech Companies
  • Database researchers
    • BioLeads
  • BioMarketplace
  • Biotech Jobs
  • Biopharma News

Tag Archives: John Wallenburg

DLVR Therapeutics – nanoparticle drug delivery system

Posted on 2014-11-17 by Biotech365

DLVR Therapeutics is developing an innovative, HDL-like Peptide-Phospholipid Scaffold (HPPS) nanoparticle delivery system, initially for RNAi therapeutics.

DLVR Therapeutics – nanoparticle drug delivery system

DLVR Therapeutics

Continue reading →

Posted in Biotech Companies, Biotech Companies Canada | Tagged antibodies, apoA-I, apoA-I mimetic peptides, apoA-I protein, aptamers, Brian Barber, chemotherapeutics, contrast agents, DLVR, DLVR Therapeutics, DLVR Therapeutics - nanoparticle drug delivery system, DLVRTherapeutics, Franco Rossetto, Frank Gleeson, Gang Zheng, HDL-like Peptide-Phospholipid Scaffold, HDL-mimicking nanoparticle, HPPS, Jeff Courtney, John Wallenburg, liposome, MaRS Innovation, mimetic peptides, nanoparticle, nanoparticle delivery system, nanoparticle drug delivery system, nanoparticles, peptides, Pharmacokinetic, photodynamic therapy agents, Raphael Hofstein, RNAi, RNAi Therapeutic, RNAi therapeutics, siRNA, siRNA therapeutic, siRNA therapeutics, small bioactive molecules, small interfering RNA, small molecules, SR-B1, targeting nucleotide sequences, therapeutics

Follow Biotech 365 !

Follow @Biotech365

Search on Biotech 365 :

Search for Protocols :

Search on PubMed :

Eminently : be paid for your your introductions! Jobs referrals, business connections, etc…

                      About us                       Terms                       Partners                       Contact                       Offers                       RSS feed - Biotech 365                      
Proudly powered by WordPress